ME02048B - N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE - Google Patents

N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE

Info

Publication number
ME02048B
ME02048B MEP-2015-10A MEP1015A ME02048B ME 02048 B ME02048 B ME 02048B ME P1015 A MEP1015 A ME P1015A ME 02048 B ME02048 B ME 02048B
Authority
ME
Montenegro
Prior art keywords
cancer
group
compound according
leukemia
agent
Prior art date
Application number
MEP-2015-10A
Other languages
English (en)
Unknown language (me)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02048(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ME02048B publication Critical patent/ME02048B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2015-10A 2009-09-11 2010-09-09 N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE ME02048B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
EP10755044.4A EP2475368B1 (en) 2009-09-11 2010-09-09 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
ME02048B true ME02048B (me) 2015-05-20

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-10A ME02048B (me) 2009-09-11 2010-09-09 N-(4-((3-(2-AMINO-4-PIRlMIDlNIL)-2-PIRlDlNlL)OKSI)FENIL)-4-(4-METIL-2-THIENIL)- 1-FTALAZINAMIN ZA PRIMENU U TRETMANU KANCERA REZISTENTNOG NA ANTIMITOTIČKE AGENSE

Country Status (34)

Country Link
US (1) US20120028917A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818170B1 (cg-RX-API-DMAC7.html)
JP (1) JP5851403B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120082896A (cg-RX-API-DMAC7.html)
CN (1) CN102869361A (cg-RX-API-DMAC7.html)
AU (1) AU2010292225C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008325A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773838C (cg-RX-API-DMAC7.html)
CL (1) CL2012000640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120171A (cg-RX-API-DMAC7.html)
DK (1) DK2475368T3 (cg-RX-API-DMAC7.html)
EA (1) EA020526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2528485T3 (cg-RX-API-DMAC7.html)
HK (1) HK1205457A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150104T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024568T2 (cg-RX-API-DMAC7.html)
IL (1) IL218569A0 (cg-RX-API-DMAC7.html)
MA (1) MA33658B1 (cg-RX-API-DMAC7.html)
ME (1) ME02048B (cg-RX-API-DMAC7.html)
MX (1) MX2012003041A (cg-RX-API-DMAC7.html)
NZ (1) NZ598758A (cg-RX-API-DMAC7.html)
PE (1) PE20120895A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500504A1 (cg-RX-API-DMAC7.html)
PL (1) PL2475368T3 (cg-RX-API-DMAC7.html)
PT (1) PT2475368E (cg-RX-API-DMAC7.html)
RS (1) RS53807B1 (cg-RX-API-DMAC7.html)
SG (1) SG179102A1 (cg-RX-API-DMAC7.html)
SI (1) SI2475368T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500028B (cg-RX-API-DMAC7.html)
TN (1) TN2012000110A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121956A (cg-RX-API-DMAC7.html)
UA (1) UA107675C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011031842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202472B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201604517WA (en) 2013-12-03 2016-07-28 Amgen Inc Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2017181087A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) * 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
HK1173655A1 (en) 2013-05-24
ZA201202472B (en) 2012-12-27
US20120028917A1 (en) 2012-02-02
CA2773838C (en) 2016-05-31
HRP20150104T1 (xx) 2015-03-13
EP2818170B1 (en) 2018-12-05
MX2012003041A (es) 2012-06-27
PL2475368T3 (pl) 2015-05-29
KR20120082896A (ko) 2012-07-24
EA020526B1 (ru) 2014-11-28
PT2475368E (pt) 2015-02-10
AU2010292225B2 (en) 2012-12-13
CL2012000640A1 (es) 2012-09-21
CR20120171A (es) 2012-08-09
EP2818170A1 (en) 2014-12-31
SMT201500028B (it) 2015-03-05
HK1205457A1 (en) 2015-12-18
EA201270383A1 (ru) 2013-04-30
MA33658B1 (fr) 2012-10-01
AU2010292225C1 (en) 2013-06-27
CA2773838A1 (en) 2011-03-17
ES2528485T3 (es) 2015-02-10
WO2011031842A1 (en) 2011-03-17
EP2475368B1 (en) 2014-12-17
IL218569A0 (en) 2012-05-31
AU2010292225A1 (en) 2012-04-12
NZ598758A (en) 2013-12-20
DK2475368T3 (en) 2015-03-09
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
HUE024568T2 (hu) 2016-02-29
JP5851403B2 (ja) 2016-02-03
CN102869361A (zh) 2013-01-09
UA107675C2 (xx) 2015-02-10
JP2013504582A (ja) 2013-02-07
TN2012000110A1 (en) 2013-09-19
RS53807B1 (sr) 2015-06-30
PH12012500504A1 (en) 2015-04-29
TW201121956A (en) 2011-07-01
SG179102A1 (en) 2012-04-27
PE20120895A1 (es) 2012-08-19
BR112012008325A2 (pt) 2017-08-29

Similar Documents

Publication Publication Date Title
JP2013504582A5 (cg-RX-API-DMAC7.html)
Poli et al. Tumorigenic cell reprogramming and cancer plasticity: interplay between signaling, microenvironment, and epigenetics
Doroshow et al. BET inhibitors: a novel epigenetic approach
Reardon et al. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents
ES2624307T3 (es) 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
Wagner Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
ES2390237T3 (es) Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
Roulstone et al. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin–paclitaxel doublet chemotherapy
Besançon et al. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids
JP2007517071A5 (cg-RX-API-DMAC7.html)
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
NZ707534A (en) Pyrrolobenzodiazepine-antibody conjugates
JP2012082234A5 (cg-RX-API-DMAC7.html)
Seo et al. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer
Karlin et al. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies
Kasper et al. Novel treatment strategies for soft tissue sarcoma
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
Napper et al. Targeted drug discovery for pediatric leukemia
Ballout et al. Anticancer alkaloids: molecular mechanisms and clinical manifestations
RU2010145048A (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
Xiao et al. Dig the root of cancer: targeting cancer stem cells therapy
Harris et al. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
Kaur et al. Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs
JP2015518053A5 (cg-RX-API-DMAC7.html)
JP2009545609A5 (cg-RX-API-DMAC7.html)